Pfizer (PFE) stock and BioNTech (BNTX) stock in focus as FDA may not renew the authorization for their pediatric COVID shot. Read more here.

The Food and Drug Administration is considering revoking Pfizer Inc.’s authorization to sell its Covid vaccine for children under the age of 5, a move that would leave healthy kids with no available ...

This fall, it may not be possible for many parents to have a healthy child younger than age 5 immunized against COVID.

The top public health officials during Trump's first term praised mRNA vaccines. In the second term, officials seem to be retreating from them.

Those who invested in Pfizer three years ago and hung on are not thrilled. They would have done much better with a simple S&P ...

Pfizer's COVID-19 vaccine for children under five may lose FDA authorization, leading to potential supply shortages. Modern ...

A Fallen Giant Pfizer (NYSE:PFE) has been a bitter pill for investors to swallow. Down 19% from its 52-week high of $30.43 per share, PFE stock has plummeted over 50% in the past three years, a stark ...

Here are two beaten-down stocks that long-term investors might want to consider buying on the dip and holding for several ...

Robert F. Kennedy Jr., the health secretary and a longtime vaccine critic, announced in a statement Tuesday that $500 million ...

“Stratus,” originally known as Variant XFG, is the second most prominent strain of COVID in the United States. According to ...

So-called mRNA vaccines saved millions of lives during the COVID-19 pandemic — and now scientists are using that Nobel ...